Overview Financials News + Filings Key Docs Charts Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Inv. presentation Consulting agrmnt Director departure Appointed COO Appointed director
|
Organicell Regenerative Medicine, Inc. (BPSR)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
08/09/2023 |
8-K
| Completion of Acquisition or Disposition of Assets Interactive Data |
07/26/2023 |
8-K
| Quarterly results |
07/11/2023 |
8-K
| Quarterly results |
06/29/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
06/09/2023 |
8-K
| Other Events Interactive Data |
06/06/2023 |
8-K
| Investor presentation |
05/01/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
04/21/2023 |
8-K
| Quarterly results |
03/08/2023 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs:
|
"SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT , dated as of March 6, 2023, by and between ORGANICELL REGENERATIVE MEDICINE, INC., a Nevada corporation, with headquarters located at 3321 College Avenue, Suite 246, Davie, FL 33314 , and AJB CAPITAL INVESTMENTS, LLC, a Delaware limited liability company, with its address at 4700 Sheridan Street, Suite J, Hollywood, FL 33021 . WHEREAS: A. The Company and the Buyer are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by the rules and regulations as promulgated by the United States Securities and Exchange Commission under the Securities Act of 1933, as amended ; B. The Buyer desires to purchase and the Company desires to issue and sell, upon the terms and conditions s...",
"Promissory Note made in favor of AJB Capital Investments",
"Warrant issued to AJB Capital Investments" |
|
12/23/2022 |
8-K
| Quarterly results |
12/01/2022 |
8-K
| Quarterly results |
11/25/2022 |
8-K
| Quarterly results |
11/21/2022 |
8-K
| Quarterly results |
10/12/2022 |
8-K/A
| Investor presentation |
10/12/2022 |
8-K
| Investor presentation |
09/27/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
09/20/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
09/16/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
09/15/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
09/09/2022 |
8-K
| Unregistered Sales of Equity Securities, Departure of Directors or Certain Officers; Election of Directors; Appointment of Ce... |
09/06/2022 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data
Docs:
|
"PURCHASE AGREEMENT THIS PURCHASE AGREEMENT , dated as of September 1, 2022, is entered into by and between ORGANICELL REGENERATIVE MEDICINE, INC., a Nevada corporation , and TYSADCO PARTNERS, LLC, a Delaware limited liability company . WHEREAS: Subject to the terms and conditions set forth in this Agreement, the Company wishes to sell to the Investor, and the Investor wishes to purchase from the Company, up to Ten Million Dollars of the Company’ s common stock, par value $0.001 per share . The shares of Common Stock to be purchased hereunder are referred to herein as the “ Purchase Shares .” NOW THEREFORE, in consideration of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Compan...",
"TO REGISTRATION RIGHTS AGREEMENT" |
|
08/30/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
08/26/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
08/23/2022 |
8-K
| Quarterly results |
07/26/2022 |
8-K
| Appointed COO |
07/20/2022 |
8-K
| Quarterly results |
07/19/2022 |
8-K
| Quarterly results |
02/08/2022 |
8-K
| Quarterly results |
01/13/2022 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
12/29/2021 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data
Docs:
|
"Miami, FL — Organicell Regenerative Medicine, Inc. , a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, is pleased to provide its stockholders and the investment community with the following updates regarding its approved Investigational New Drug Applications and other clinical trial related activities surrounding Zofin TM , its principal product. Zofin™ , is an acellular, biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs, without the addition or combination of any other substance or diluent. This product contains over 300 growth factors, cytokines, chemokines, and 102 unique microRNAs as well as other exosomes/nanoparticles derived from perinatal tissues." |
|
11/09/2021 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data
Docs:
|
"ORGANICELL REGNERATIVE MEDICINE, INC. UPLIST OF COMMON STOCK TO OTCQB APPROVED Common Stock to trade on OTCQB under the symbol “OCEL” commencing November 9, 2021 PRESS RELEASE Miami, FL — Organicell Regenerative Medicine, Inc. , a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that its application to uplist its common stock to the OTCQB Venture Market has been approved by OTC Markets Group, Inc. Organicell’ s common stock will commence trading on the OTCQB under the symbol “OCEL” commencing at the opening of the market on November 9, 2021. The OTCQB, operated by OTC Markets Group Inc., is designed for developing and entrepreneurial companies in the United States and abroad. To be listed on OTCQB, companies must be current in..." |
|
11/05/2021 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data
Docs:
|
"Miami, FL — Organicell Regenerative Medicine, Inc. , a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that it has received confirmation from the Financial Industry Regulatory Agency that the pending marketplace name change and trading symbol change request to Organicell Regenerative Medicine, Inc. and “OCEL” has been approved. Accordingly, effective Monday November 8, 2021, the company will have the marketplace name Organicell Regenerative Medicine, Inc. and Organicell common stock will begin trading under the symbol “OCEL” on the OTCPink tier of the over-the -counter market operated by OTC Markets Group, Inc. · New Marketplace Name: Organicell Regenerative Medicine, Inc. · New Symbol: OCEL · New CUSIP: ..." |
|
11/02/2021 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits ... |
08/31/2021 |
8-K
| Quarterly results |
|
|
|